London, 08 May 2015: Technavio, the independent tech-focused global research firm, has published a report on the global diabetic retinopathy market 2015-2019, which is expected to grow at a CAGR of 6.89 % during the forecast period of 2014-2019.
Diabetic retinopathy mostly develops with diabetes, thus the increased prevalence of diabetes propels the global diabetic retinopathy market. The disorder affects about 366 million individuals worldwide at present and is expected to exceed half a billion by 2030.
“The launch of new FIC therapies, such as anti-VEGF, protein kinase inhibitors and prostaglandin h-synthase inhibitors, will propel market growth in the future. These new drugs have the potential to fulfill the current unmet medical needs of the market and cause the competition among vendors to intensify,” says Faisal Ghaus, Vice President of Technavio.
“The introduction of Macugen by Pfizer and Lucentis by Novartis, which are specifically indicated for diabetic macular edema, as well as the label expansion of currently available agents that have been used as off-labels, will drive market growth.”
Key Market Drivers
- Increased Patient Population
- Unmet Medical Needs
- Improved Diagnostic Procedures
Key Market Trends
- Launch of Novel Drugs
- Combination Therapies
- Strategic Alliances
- Use of Anti-VEGF Therapies
Key Market Vendors
- Bayer AG
- F. Hoffmann-La Roche Ltd.
- Novartis International AG
- Regeneron Pharmaceuticals Inc.
To define the market circumstances in the next 3-4 years, Technavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
If you are interested in more information on this topic and our upcoming research on the Global Diabetic Retinopathy Market 2015-2019; please send an e-mail to media@Technavio.com.
Follow us on Twitter @Technavio
Like us on Facebook
Follow us LinkedIn
Connect with us on Google+
